Beta Drugs Limited (NSE:BETA)
India · Delayed Price · Currency is INR 1,423.40
-6.10 (-0.43%)
At close: Jun 1, 2026
Beta Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 3,848 | 3,624 | 2,957 | 2,271 | 1,838 | |
Revenue Growth (YoY) | 6.20% | 22.54% | 30.20% | 23.54% | 58.31% |
Cost of Revenue | 1,712 | 2,124 | 1,814 | 1,297 | 1,123 |
Gross Profit | 2,136 | 1,500 | 1,143 | 974.47 | 714.89 |
Selling, General & Admin | 680.06 | 380.45 | 276.67 | 242.78 | 169.97 |
Other Operating Expenses | 699.62 | 373.16 | 267.57 | 197.32 | 117.94 |
Operating Expenses | 1,551 | 878.75 | 642.06 | 544.2 | 360.45 |
Operating Income | 585.25 | 620.91 | 501.31 | 430.27 | 354.44 |
Interest Expense | -153.11 | -67.41 | -26.78 | -22.8 | -17.89 |
Interest & Investment Income | - | 51.1 | 10.84 | 6.63 | 4.52 |
Currency Exchange Gain (Loss) | - | - | 0.84 | -3.09 | 0.43 |
Other Non Operating Income (Expenses) | 111.8 | 10.78 | 1.33 | -0.44 | 1.51 |
EBT Excluding Unusual Items | 543.94 | 615.38 | 487.54 | 410.57 | 343.01 |
Other Unusual Items | - | -45.7 | - | - | - |
Pretax Income | 543.94 | 569.69 | 487.54 | 410.57 | 343.01 |
Income Tax Expense | 129.11 | 145.5 | 123.17 | 103.38 | 94.74 |
Net Income | 414.83 | 424.19 | 364.37 | 307.19 | 248.28 |
Net Income to Common | 414.83 | 424.19 | 364.37 | 307.19 | 248.28 |
Net Income Growth | -2.21% | 16.42% | 18.62% | 23.73% | 111.76% |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 |
Shares Change (YoY) | 0.43% | 5.00% | -4.76% | - | - |
EPS (Basic) | 40.92 | 42.02 | 37.90 | 30.43 | 24.60 |
EPS (Diluted) | 40.92 | 42.02 | 37.90 | 30.43 | 24.59 |
EPS Growth | -2.62% | 10.87% | 24.55% | 23.74% | 111.72% |
Free Cash Flow | -161.95 | -7.14 | 193.15 | 51.71 | 102 |
Free Cash Flow Per Share | -15.98 | -0.71 | 20.09 | 5.12 | 10.11 |
Gross Margin | 55.52% | 41.39% | 38.66% | 42.91% | 38.89% |
Operating Margin | 15.21% | 17.14% | 16.95% | 18.95% | 19.28% |
Profit Margin | 10.78% | 11.71% | 12.32% | 13.53% | 13.51% |
Free Cash Flow Margin | -4.21% | -0.20% | 6.53% | 2.28% | 5.55% |
EBITDA | 756.78 | 734.66 | 599.13 | 534.37 | 426.98 |
EBITDA Margin | 19.67% | 20.28% | 20.26% | 23.53% | 23.23% |
D&A For EBITDA | 171.53 | 113.75 | 97.82 | 104.1 | 72.54 |
EBIT | 585.25 | 620.91 | 501.31 | 430.27 | 354.44 |
EBIT Margin | 15.21% | 17.14% | 16.95% | 18.95% | 19.28% |
Effective Tax Rate | 23.74% | 25.54% | 25.26% | 25.18% | 27.62% |
Revenue as Reported | 3,960 | 3,688 | 2,971 | 2,279 | 1,846 |
Advertising Expenses | - | 35.6 | 14.57 | 12.57 | 8 |